Announced details
Treatment of head lice in patients for whom existing treatments are insufficiently effective
Treatment success rate among index subjects: 85.2% in the KAR group (23/27 subjects) and 7.4% in the vehicle group (2/27 subjects), a between-group difference of 77.8 (95% confidence interval: 55.63, 89.66; P<0.001). Among all subjects, the treatment success rate was 87.5% in the KAR group (49/56 subjects) and 9.8% in the vehicle group (6/61 subjects), a between-group difference of 77.7 (95% confidence interval: 63.60, 86.74; P<0.001)
Kaken Pharmaceutical presented the results of the domestic Phase III trial of KAR, for which it has filed a marketing authorization application. Equity and personnel relationships: Not disclosed.
An academic meeting held in Kyoto from 11 to 14 June 2026. Other details: Not disclosed.
Kaken Pharmaceutical headquarters: Bunkyo-ku, Tokyo
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Results of the domestic Phase III trial presented at the 125th Annual Meeting of the Japanese Dermatological Association
| Item | Details |
|---|---|
| Names of Products / Services Covered | KAR (generic name: ivermectin) |
| Counterparty | 125th Annual Meeting of the Japanese Dermatological Association (Japanese Dermatological Association) |
| Counterparty overview | An academic meeting held in Kyoto from 11 to 14 June 2026. Other details: Not disclosed. |
| Relationship with the Company | Kaken Pharmaceutical presented the results of the domestic Phase III trial of KAR, for which it has filed a marketing authorization application. Equity and personnel relationships: Not disclosed. |
| Applicable area | Treatment of head lice in patients for whom existing treatments are insufficiently effective |
| Location | Kaken Pharmaceutical headquarters: Bunkyo-ku, Tokyo |
| Quantitative Effects | Treatment success rate among index subjects: 85.2% in the KAR group (23/27 subjects) and 7.4% in the vehicle group (2/27 subjects), a between-group difference of 77.8 (95% confidence interval: 55.63, 89.66; P<0.001). Among all subjects, the treatment success rate was 87.5% in the KAR group (49/56 subjects) and 9.8% in the vehicle group (6/61 subjects), a between-group difference of 77.7 (95% confidence interval: 63.60, 86.74; P<0.001) |
| Source | Results of the domestic Phase III trial presented at the 125th Annual Meeting of the Japanese Dermatological Association |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To confirm the efficacy of the product in treating head lice where existing treatments have been insufficiently effective. In recent years, head lice showing resistance to existing treatment products have increased, particularly in Okinawa Prefecture, creating a treatment challenge.